<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Annals of the Russian academy of medical sciences</journal-id><journal-title-group><journal-title xml:lang="en">Annals of the Russian academy of medical sciences</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник Российской академии медицинских наук</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0869-6047</issn><issn publication-format="electronic">2414-3545</issn><publisher><publisher-name xml:lang="en">"Paediatrician" Publishers LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">614</article-id><article-id pub-id-type="doi">10.15690/vramn614</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ONCOLOGY: CURRENT ISSUES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>АКТУАЛЬНЫЕ ВОПРОСЫ ОНКОЛОГИИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">The effects of cysplatin on human adipose tissue derived mesenchymal stromal cells under different oxygen levels</article-title><trans-title-group xml:lang="ru"><trans-title>Воздействие цисплатина на мультипотентные мезенхимные стромальные клетки жировой ткани человека при различном уровне кислорода</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Rylova</surname><given-names>Yu. V.</given-names></name><name xml:lang="ru"><surname>Рылова</surname><given-names>Юлия Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD in Biology</p></bio><bio xml:lang="ru"><p>Кандидат биологических наук, научный сотрудник лаборатории клеточной физиологии. </p><p>Адрес: 123007, Москва, ул. Хорошевское шоссе, д. 76а</p></bio><email>yuliaril@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Buravkova</surname><given-names>L. B.</given-names></name><name xml:lang="ru"><surname>Буравкова</surname><given-names>Людмила Борисовна</given-names></name></name-alternatives><bio xml:lang="en"><p>MD, PhD, Professor, Corresponding Member of RAS, Deputy Director</p></bio><bio xml:lang="ru"><p>Доктор медицинских наук, профессор, член-корреспондент РАН, заместитель директора по науке, заведующая лабораторией клеточной физиологии. </p><p>Адрес: 123007, Москва, ул. Хорошевское шоссе, д. 76а</p></bio><email>buravkova@imbp.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Zhivotovky</surname><given-names>B. D.</given-names></name><name xml:lang="ru"><surname>Животовский</surname><given-names>Борис Давидович</given-names></name></name-alternatives><bio xml:lang="en"><p>PhD in Biology, Professor, Head of Laboratory</p></bio><bio xml:lang="ru"><p>Доктор биологических наук, заведующий лабораторией исследования механизмов апоптоза, профессор кафедры фармацевтической химии, факультета фундаментальной медицины.</p><p>Адрес: 119991, Москва, Ломоносовский пр., д. 27 корп. 1,</p></bio><email>Boris.Zhivotovsky@ki.se</email><xref ref-type="aff" rid="aff3"/><xref ref-type="aff" rid="aff4"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Institute of Biomedical Problems, Russian Academy of Sciences, Moscow</institution></aff><aff><institution xml:lang="ru">Институт медико-биологических проблем РАН, Москва</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Lomonosov Moscow State University</institution></aff><aff><institution xml:lang="ru">Московский Государственный Университет имени М.В. Ломоносова</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Lomonosov Moscow State University</institution></aff><aff><institution xml:lang="ru">Московский государственный университет имени М.В. Ломоносова</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Institute of Environmental Medicine, Karolinska Institutet, Stockholm</institution></aff><aff><institution xml:lang="ru">Каролинский институт, Стокгольм</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2016-05-07" publication-format="electronic"><day>07</day><month>05</month><year>2016</year></pub-date><volume>71</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>114</fpage><lpage>120</lpage><history><date date-type="received" iso-8601-date="2016-02-06"><day>06</day><month>02</month><year>2016</year></date><date date-type="accepted" iso-8601-date="2016-02-06"><day>06</day><month>02</month><year>2016</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2016, "Paediatrician" Publishers LLC</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2016, Издательство "Педиатръ"</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="en">"Paediatrician" Publishers LLC</copyright-holder><copyright-holder xml:lang="ru">Издательство "Педиатръ"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2017-05-07"/></permissions><self-uri xlink:href="https://vestnikramn.spr-journal.ru/jour/article/view/614">https://vestnikramn.spr-journal.ru/jour/article/view/614</self-uri><abstract xml:lang="en"><p><bold><italic>Objective:</italic></bold> To evaluate the damaging effects of cisplatin on MMSCs from adipose tissue in a phase of active proliferation and the state of the monolayer, which was exposed at standard (20%) and reduced to 1% and 5% level of oxygen.</p><p><bold><italic>Methods:</italic></bold> The incubation MMSC with cisplatin was performed on cultures of 2 passage in a state in monolayer and cultures in the active growth phase. Profile surface markers of MMSC determined by flow cytometry. MMSCs viability after incubation with cisplatin was detected by the number of apoptotic and necrotic cells using ANNEXIN V-FITC - PI Kit (Immunotech, France). Standard culture conditions (~ 20% O<sub>2</sub>) created in a CO<sub>2 </sub>incubator (Sanyo, Japan), 5% O<sub>2</sub> created using multigas incubator (Sanyo, Japan), 1% O<sub>2</sub> - using an airtight chamber (Stemcell Technologies, USA).</p><p><bold><italic>Results:</italic></bold> Incubation of monolayer MMSC with cisplatin at a concentration of 10 ug/ml for 72 hours leads to death of half of the cells in culture under 20% O<sub>2</sub>, 5% O<sub>2</sub> and 1% O<sub>2</sub>. Cisplatin increased the fracture of PI<sup>+</sup>-cell, and PI<sup>+</sup>/Ann<sup>+</sup>-cells under all culture conditions. The short-term exposure with cisplatin (24 and 48 hours) did not cause the damaging effect. Effects of cisplatin on the MMSC in the growth phase for 48 hours led to accumulation of Ann<sup>+</sup>-cells and PI<sup>+</sup>/Ann <sup>+</sup>-cells under all culture conditions. However least damaging effect of cisplatin was observed in culture under hypoxic conditions (1% O<sub>2</sub>).</p><p><bold><italic>Conclusion:</italic></bold> These data suggest that monolayer MMSCs are dying primarily through necrosis, whereas MMSC in the growth phase in response to cisplatin treatment are dying by apoptosis, regardless the oxygen tension.</p></abstract><trans-abstract xml:lang="ru"><p><bold><italic>Цель исследования: </italic></bold>оценить повреждающее воздействие цисплатина на ММСК жировой ткани, находящиеся в фазе активной пролиферации и в состоянии монослоя, при стандартном (20%) и сниженном до 1% и 5% уровне кислорода в среде культивирования.</p><p><bold><italic>Методы: </italic></bold>Оценку влияния цисплатина на ММСК проводили на культурах 2 пассажа в состоянии монослоя и в культурах в активной фазе роста. Профиль поверхностных маркеров ММСК определяли с помощью проточной цитофлуориметрии. Жизнеспособность ММСК после инкубации с цисплатином оценивали по количеству апоптотических и некротических клеток с помощью набора ANNEXIN V-FITC – PI (Immunotech, Франция). Стандартные условия культивирования (~20% О<sub>2</sub>) создавали в СО<sub>2</sub>-инкубаторе (Sanyo, Япония), 5% О<sub>2</sub> создавали используя мультигазовый инкубатор (Sanyo, Япония), 1% О<sub>2</sub> – используя герметичную камеру (Stemcell Technologies, США).</p><p><bold><italic>Результаты: </italic></bold>Инкубация ММСК в состоянии монослоя с цисплатином в концентрации 10 мкг/мл в течение 72 часов вызывала гибель практически половины клеток в культуре как при 20% О<sub>2</sub>, так и при 5% и 1% О<sub>2</sub> в среде. Во всех условиях культивирования увеличивалась доля PI<sup>+</sup>-клеток и PI<sup>+</sup>/Ann<sup>+</sup>-клеток. Более кратковременные экспозиции с цисплатином (24 и 48 часов) не оказывали выраженного повреждающего эффекта. Воздействие цисплатина на ММСК в активной фазе роста в течение 48 часов сопровождалось накоплением количества Ann<sup>+</sup>-клеток и PI<sup>+</sup>/Ann<sup>+</sup>-клеток. При этом наименьшее повреждающее воздействие цисплатин оказал на клетки, культивируемые в условиях гипоксии (1% О<sub>2</sub>).</p><p><bold><italic>Заключение: </italic></bold>Полученные данные свидетельствуют, что ММСК в состоянии монослоя погибают преимущественно путем некроза, тогда как для культур ММСК в фазе роста в ответ на воздействие было характерно накопление клеток, погибающих путем апоптоза, вне зависимости от уровня содержания кислорода в среде.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>мультипотентные мезенхимные стромальные клетки</kwd><kwd>гипоксия</kwd><kwd>цисплатин</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">РФФИ №14-04-00933</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Harvey RL, Chopp M. The therapeutic effects of cellular therapy for functional recovery after brain injury. Phys Med Rehabil Clin N Am. 2003;14(1):143–151. doi:10.1016/s1047-9651(02)00058-x.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>2. Horwitz EM, Gordon PL, Koo WK, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA. 2002;99(13):8932–8937. doi:10.1073/pnas.132252399.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>3. Stamm C, Kleine HD, Westphal B, et al. CABG and bone marrow stem cell transplantation after myocardial infarction. Thorac Cardiovasc Surg. 2004;52(3):152–158. doi:10.1055/s-2004-817981.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>4. Seifrtova M, Havelek R, Cmielova J, et al. The response of human ectomesenchymal dental pulp stem cells to cisplatin treatment. International Endodontic Journal. 2011;45(5):401–412. doi: 10.1111/j.1365-2591.2011.01990.x.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>5. Momekov G, Ferdinandov D, Bakalova A, et al. In vitro toxicological evaluation of a dinuclear platinum (II) complex with acetate ligands. Arch Toxicol. 2006;80(9):555–560. doi:10.1007/s00204-006-0078-0.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>6. Shaked Y, Henke E, Roodhart JM, et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell. 2008;14(3):263–273. doi: 10.1016/j. ccr.2008.08.001.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>7. Chen MF, Lin CT, Chen WC, et al. The sensitivity of human mesenchymal stem cells to ionizing radiation. Int J Rad Oncol Biol Phys. 2006;66(1):244–253. doi:10.1016/j.ijrobp.2006.03.062.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>8. Li J, Law HK, Lau YL, et al. Differential damage and recovery of human mesenchymal stem cells after exposure to chemotherapeutic agents. Br J Haematol. 2004;127(3):326–334. doi:10.1111/j.1365-2141.2004.05200.x.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>9. Mueller LP, Luetzkendorf J, Mueller T, et al. Presence of mesenchymal stem cells in human bone marrow after exposure to chemotherapy: evidence of resistance to apoptosis induction. Stem Cells (Dayton, Ohio). 2006;24(12):2753–2765. doi:10.1634/stemcells.2006-0108.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>10. Young HE, Steele TA, Bray RA, et al. Human reserve pluripotent mesenchymal stem cells are present in the connective tissues of skeletal muscle and dermis derived from fetal, adult, and geriatric donors. Anat Rec. 2001;264(1):51–62. doi:10.1002/ar.1128.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>11. Ahn JM, You SJ, Lee YM, et al. Hypoxia inducible factor activation protects the kidney from gentamicin-induced acute injury. PLoS One. 2012;7(11):e48952. doi: 10.1371/journal.pone.0048952.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>12. Zarjou A, Kim J, Traylor AM, et al. Paracrine effects of mesenchymal stem cells in cisplatin-induced renal injury require heme oxygenase–1. Am J Physiol Renal Physiol. 2011;300(1):254–262. doi: 10.1152/AJPRENAL.00594.2010.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>13. Wang WW, Wang W, Jiang Y, et al. Human adipose derived stem cells modified by HIF-1a accelerate the recovery of cisplatin induced acute renal injury in vitro. Biotechnol Lett. 2014;36(3):667−676. doi: 10.1007/s10529-013-1389-x.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>14. Zhou Y, Xu H, Xu W, et al. Exosomes released by human umbilical cord mesenchymal stem cells protect against cisplatin induced renal oxidative stress and apoptosis in vivo and in vitro. Stem Cell Research &amp; Therapy. 2013;4(2):34. doi: 10.1186/scrt194.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>15. Buravkova LB, Rylova YV, Andreeva ER, et al. Low ATP level is sufficient to maintain the uncommitted state of multipotent mesenchymal stem cells. Biochimica et Biophysica Acta. 2013;1830:4418–25. doi: 10.1016/j.bbagen.2013.05.029.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>16. Fehrer C, Brunauer R, Laschober G, et al. Reduced oxygen tension attenuates differentiation capacity of human mesenchymal stem cells and prolongs their lifespan. Aging Cell. 2007;6(6):745−757. doi: 1 0.1111/j.1474-9726.2007.00336.x.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>17. Буравкова Л.Б., Гринаковская О.С., Андреева Е.Р., Жамбалова А.П., Козионова М.П. Характеристика мезенхимных стромальных клеток из липоаспирата человека, культивируемых при пониженном содержании кислорода // Цитология. – 2009. – Т. 51. – №1. – С. 5–11. [Buravkova LB, Grinakovskaya OS, Andreeva ER, et al. Characteristics of human lipoaspirate-isolated mesenchymal stromal cells cultivated under lower oxygen tension. Cell tissue biol. 2009;51(1):5–11. (In Russ.)] doi: 10.1134/S1990519X09010039</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>18. Хаитов Р.М., Пинегин Б.В., Ярилин А.А. Руководство по клинической иммунологии: диагностика заболеваний иммунной системы: руководство для врачей. – М.: ГЭОТАР-Медиа; 2009. 352 с. [Khaitov RM, Pinegin BV, Yarilin AA. Rukovodstvo po klinicheskoi immunologii: diagnostika zabolevanii immunnoi sistemy: rukovodstvo dlya vrachei. Moscow: GEOTAR-Media; 2009. 352 p. (In Russ.)]</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>19. Pober JS, Gimbrone MA Jr, Lapierre LA, et al. Overlapping patterns of activation of human endothelial cells by interleukin–1, tumor necrosis factor, and immune interferon. J Immunol. 1986;137(6):1893–1896.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>20. Liang W, Lu C, Li J, et al. p73α regulates the sensitivity of bone marrow mesenchymal stem cells to DNA damage agents. Toxicology. 2010;270(1):49–56. doi: 10.1016/j.tox.2010.01.011.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>21. Liang W, Xia H, Li J, et al. Human adipose tissue derived mesenchymal stem cells are resistant to several chemotherapeutic agents. Cytotechnology. 2011;63(5):523–530. doi: 10.1007/s10616-011-9374-5.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>22. Greijer AE, van der Wall E. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol. 2004;57(10):1009–1014.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>23. Bhang SH, Cho SW, Lim JM. Locally delivered growth factor enhances the angiogenic efficacy of adipose-derived stromal cells transplanted to ischemic limbs. Stem Cells. 2009;27(8):1976–1986. doi: 10.1002/stem.115.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>24. Stubbs SL, Hsiao ST, Peshavariya HM, et al. Hypoxic preconditioning enhances survival of human adipose derived stem cells and conditions endothelial cells in vitro. Stem Cells Dev. 2012;21(11):1887–1896. doi: 10.1089/scd.2011.0289.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>25. Doktorova H, Hrabeta J, Khalil MA, et al. Hypoxia induced chemoresistance in cancer cells: The role of not only HIF-1. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159(2):166−177. doi: 10.5507/bp.2015.025.</mixed-citation></ref></ref-list></back></article>
